GLP-1s May Reduce Inflammation
8 Sept 2026 · 0 min
0:27
In this segment, Dr. Betty Murray highlights findings from major clinical trials of GLP‑1 receptor agonists—specifically semaglutide and tirzepatide—showing that levels of high‑sensitivity C‑reactive protein (hs‑CRP), a marker of systemic inflammation, drop markedly. Crucially, the reduction in inflammation occurs independently of any weight‑loss effects, suggesting a direct anti‑inflammatory action of these drugs.
